Skip to main content
. 2021 Jan 6;15(8):505–516. doi: 10.5797/jnet.oa.2020-0170

Table 1. Summary of baseline characteristics.

Variable Study cohort (n = 43)
Age, years 72.0 (68.0–76.5)
Female sex 6 (14.0%)
Hypertension 36 (83.7%)
Diabetes mellitus 17 (39.5%)
Hyperlipidemia 23 (53.5%)
Coronary artery disease 2 (4.7%)
Current smoking 12 (27.9%)
Statin 34 (79.1%)
Proton pump inhibitor 36 (83.7%)
Cilostazol 2 (4.7%)
Oral anti-coagulant 3 (7.0%)
Duration of clopidogrel use before treatment, days 27 (18.5–85.5)
Hemoglobin, g/dL 13.9 (12.6–14.5)
Platelets, ×103/mL 21.2 (18.6–25.6)
Serum albumin, mg/dL 4.2 (3.9–4.4)
Symptomatic lesion 21 (48.8%)
NASCET, %* 69.3 (62.5–79.9)
General anesthesia 42 (97.7%)
9-Fr guiding catheter 36 (83.7%)
Closed stent 35 (81.4%)
Flow reversal 35 (81.4%)

Continuous variables are presented as median (interquartile range).

* The degree of carotid artery stenosis measured using the NASCET method.

NASCET: North American Symptomatic Carotid Endarterectomy Trial